Phytochemicals from *Vanda bensonii* and Their Bioactivities to Inhibit Growth and Metastasis of Non-Small Cell Lung Cancer Cells

Tajudeen O. Jimoh 1,2, Narawat Nuamnaichati 3, Rungroch Sunghong 3, Chaisak Chansriniyom 4,5, Pithi Chanvorachote 6,7, Kittisak Likhitwitayawuid 4, Chatchai Chaotham 3,7,8, and Boonchoo Sritularak 4,8,*

1 Pharmaceutical Sciences and Technology Program, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
2 Department of Biochemistry, Faculty of Health Sciences, Islamic University in Uganda, Kampala PO. Box 7689, Uganda
3 Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
4 Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
5 Natural Products and Nanoparticles Research Unit, Chulalongkorn University, Bangkok 10330, Thailand
6 Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
7 Center of Excellence in Cancer Cell and Molecular Biology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
8 Center of Excellence in Natural Products for Ageing and Chronic Diseases, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand

*Correspondence: cchoatham@gmail.com (C.C.); boonchoo.sr@chula.ac.th (B.S.); Tel.: +66-(0)-2218-8372 (C.C.); +66-(0)-2218-8356 (B.S.)

Abstract: The most prevalent lung cancer is non-small cell lung cancer (NSCLC). This lung cancer type often develops other organ-specific metastases that are critical burdens in the treatment process. Orchid species in the genus *Vanda* have shown their potential in folkloric medication of diverse diseases but not all its species have been investigated, and little is known about their anticancer activities against NSCLC. Here, we firstly profiled the specialized metabolites of *Vanda bensonii* and examined their capability to inhibit growth and metastasis of NSCLC using NCI-H460 cells as a study model. Four phytochemicals, including phloretic acid methyl ester (1), cymbinodin-A (2), ephemerranthoquinone B (3), and protocatechuic acid (4), were isolated from the whole plant methanolic extract of *V. bensonii*. The most distinguished cytotoxic effect on NCI-H460 cells was observed in the treatments with crude methanolic extract and compound 2 with the half maximal inhibitory concentrations of 40.39 µg mL⁻¹ and 50.82 µM, respectively. At non-cytotoxic doses (10 µg mL⁻¹ or 10 µM), only compound 1 could significantly limit NCI-H460 cell proliferation when treated for 48 h, while others excluding compound 4 showed significant reduction in cell proliferation after treating for 72 h. Compound 1 also significantly decreased the migration rate of NCI-H460 cells examined through a wound-healing assay. Additionally, the crude extract and compound 1 strongly affected survival and growth of NCI-H460 cells under anchorage-independent conditions. Our findings proved that natural products from *V. bensonii* could be promising candidates for the future pharmacotherapy of NSCLC.

Keywords: *Vanda bensonii*; phytochemicals; lung cancer; anticancer; metastasis; cytotoxicity; cell proliferation; cell migration; anchorage-independent growth

1. Introduction

The genus *Vanda* in the family Orchidaceae is among the five most horticulturally important orchid genera in the world, which contains over 70 member species found across
Southern and Southeastern Asia [1]. They are mostly epiphytes, while some can have lithophytic and monopodial growth features. Some of them are employed as unrefined drugs with a domestic cognomen “Rasna” in Ayurvedic medicine [2]. Their folkloric medical uses are also perceived across Nepal, Thailand, India, Bangladesh, and many other countries in South Asia [3]. Several Vanda species (e.g., Vanda testacea, Vanda cristata, Vanda parviflora, Vanda spathulata, and Vanda roxburghii) have been unveiled for their medical applications in the treatment of diverse illnesses [2,3]. Although Vanda species have shown their recognized healing capabilities, further in-depth studies on their elucidated bioactive molecules are essential to extend their pharmaceutical and medical implementations.

In Indian folkloric medicine, the juice from Vanda coerulea leaves can improve indigestion and diarrhea [4], while its flower decoction is applied as a tonic and appetizer [5]. Similarly, the paste made from the roots or whole plants of V. cristata is used to treat dislocated bones and heal varieties of skin wounds [6], while its leaf extracts exhibit curing capacities for cough, bronchitis, weakness, and tonsillitis [4]. Interestingly, applying different forms of Vanda crude mixtures containing varying bioactive compounds for healing diseases is a promising and straightforward medication to support human well-being. Some further studies proved that Vanda plants are the rich sources of bibenzyls, phenanthrenes, anthocyanins, and simple phenolic compounds, which exert some promising pharmaceutical properties, e.g., hepatoprotective, antioxidant, anticonvulsant, anti-inflammatory, and anti-aging [2,3,7,8]. Only few reviews reported anticancer activities of V. parviflora [2,3], but the relevant research evidence is rarely available. To our knowledge, Vanda phytochemicals and their roles in cancer therapy are yet scarce.

Based on the global prevalence and mortality rate, 2,206,771 (11.4%) new cases and 1,796,144 (18.0%) new deaths were recorded for patients with lung cancer [9]. Among all lung cancer cases, patients with non-small cell lung cancer (NSCLC) are the majority (approximately over 80% [10]) compared to those with small cell lung cancer (SCLC). Unlike SCLC that is faster in disease progression and greater severity, slower progress in NSCLC results in the late-phase detection of the disease and allows the emergence of secondary malignant growths at other sites of the body, so-called “metastasis”. NSCLC patients have been prognosticated to have bone, brain, and many other organ-specific metastases [11,12]. Metastasis involves cancer cell migration, leading to survival and growth under anchorage-independent conditions. This aggressive feature of cancer cells is one of the major impediments in cancer therapy, which still requires advanced therapeutic approaches and more effective medicines with fewer or no side effects. Hence, exploiting pharmaceutical benefits of natural products to inhibit growth and metastasis of NSCLC cells is yet a scientific challenge in the development of alternative treatments to defeat lung cancer.

Among the notable Vanda species in Thailand [13], Vanda bensonii Batem., with Thai name “Sam Poi Chomphu,” is an economically important orchid species due to its beautifully unique flower features (Figure 1). This Vanda species is still unknown for its chemical constituents and their pharmaceutical potential. Unveiling the phytochemical profile of this Vanda species would benefit orchid chemotaxonomy and enhance its ethnopharmacology. In this study, we profiled the specialized metabolites of V. bensonii cultivated in Thailand and elucidated their capability to inhibit growth and metastasis of NSCLC cells using the human NCI-H460 cells as a studied model. These NSCLC cells were chosen based on their origin from pleural fluid, which represent high metastatic features, including capability to grow under anchorage-independent conditions [14].
Molecules 2022, 27, x FOR PEER REVIEW 3 of 14

Figure 1. Vanda bensonii and its specialized metabolites. Phytochemicals isolated from the methanolic extract of this orchid plant include phloretic acid methyl ester (1), cymbinodin-A (2), ephemeranthoquinone B (3), and protocatechuic acid (4).

2. Results

2.1. Key Phytochemicals Isolated from V. bensonii

From the methanolic extract prepared from the whole V. bensonii plant, a variety of specialized metabolites, including phloretic acid methyl ester (1), cymbinodin-A (2), ephemeranthoquinone B (3), and protocatechuic acid (4), were isolated (Figure 1 and Table 1). The chemical structures of each compound were characterized by extensive spectroscopic studies, including 1D and 2D-NMR as well as HR-ESI-MS experiments.

Phloretic acid methyl ester (1): White powder; HR-ESI-MS: [M+Na]⁺ at m/z 203.0674 (calcd. for 203.0684, C₁₀H₁₂O₃Na); ¹H NMR (400 MHz, acetone-δ) δ: 8.13 (1H, s, HO-4), 7.04 (2H, d, J = 8.4 Hz, H-2, H-6), 6.74 (2H, d, J = 8.4 Hz, H-3, H-5), 3.60 (3H, s, MeO-9), 2.80 (2H, t, J = 7.6, H₂-7), 2.54 (2H, t, J = 7.6, H₂-8); ¹³C NMR (100 MHz, acetone-d₆) δ: 173.5 (C-9), 156.7 (C-4), 132.5 (C-2), 130.2 (C-3, C-6), 116.1 (C-1, C-5), 51.6 (MeO-9), 36.6 (C-8), 30.6 (C-7) (Figure 1).

Cymbinodin-A (2): Red amorphous solid; HR-ESI-MS: [M+H]⁺ at m/z 255.0650 (calcd. for 255.0657, C₁₅H₁₉O₄); ¹H NMR (400 MHz, acetone-d₆) δ: 12.35 (1H, s, HO-5), 8.34 (1H, d, J = 8.8 Hz, H-9), 8.14 (1H, d, J = 8.8 Hz, H-10), 7.63 (1H, dd, J = 7.6, 8.0 Hz, H-7), 7.55 (1H, dd, J = 8.0, 1.6 Hz, H-8), 7.16 (1H, dd, J = 7.6, 1.6 Hz, H-6), 6.50 (1H, s, H-3), 4.05 (3H, s, MeO-2); ¹³C NMR (100 MHz, acetone-d₆) δ: 193.5 (C-4), 180.6 (C-1), 160.5 (C-2), 156.7 (C-5, C-7), 140.0 (C-8a), 138.1 (C-9), 133.8 (C-10a), 131.6 (C-7), 130.9 (C-4a), 122.6 (C-10), 121.8 (C-8), 117.8 (C-6), 112.4 (C-3), 57.3 (MeO-2) (Figure 1).

Ephemeranthoquinone B (3): Red amorphous solid; HR-ESI-MS: [M+Na]⁺ at m/z 279.0633 (calcd. for 279.0633, C₁₅H₁₉O₄Na); ¹H NMR (400 MHz, acetone-d₆) δ: 9.65 (1H, s,
HO-5), 7.21 (1H, dd, J = 7.6, 8.0 Hz, H-7), 6.81 (2H, br d, J = 8.0 Hz, H-6, H-8), 6.18 (1H, s, H-3), 3.94 (3H, s, MeO-2), 2.72 (2H, m, H$_2$-9), 2.58 (2H, m, H$_2$-10); $^{13}$C NMR (100 MHz, acetone-$_d_6$): δ: 191.5 (C-4), 181.3 (C-1), 160.0 (C-2), 156.4 (C-5), 143.8 (C-10a), 142.1 (C-8a), 139.8 (C-4a), 132.6 (C-7), 120.6 (C-8), 118.9 (C-6), 118.6 (C-4b), 108.9 (C-3), 57.2 (MeO-2), 29.1 (C-9), 21.9 (C-10) (Figure 1).

Some bioactivities of phytochemicals derived from _V. bensonii_ 115.5 (C-5) (Figure 1).

### 2.2. The Orchid Metabolites Exhibit a Broad Spectrum of Anticancer Activities

Cytotoxic effects of the crude methanolic extract and each isolated compound from _V. bensonii_ varied depending upon the tested compounds and concentrations (Figure 2 and Table 1). The crude methanolic extract at 25 µg mL$^{-1}$ started to reduce NCI-H460 cell viability significantly (Figure 2a), while cymbinodin-A (2) at 25 µM started to show cytotoxic effects (Figure 2e). The absolute half maximal inhibitory concentration (absolute IC$_{50}$) value (Table 1) computed from the sigmoidal dose-response plots (Supplementary Materials Figure S1) was 40.39 µg mL$^{-1}$ for the crude methanolic extract and 50.82 µM for cymbinodin-A (2). Phloretic acid methyl ester (1) and ephemeranthoquinone B (3) showed cytotoxic effects on NCI-H460 cells starting from their concentration at 50 µM (Figure 2c,g), while protocatechuic acid (4) did not exhibit cytotoxicity up to the maximum tested concentration of 100 µM (Figure 2i). The absolute IC$_{50}$ value for ephemeranthoquinone B (3) (64.22 µM) was greater than that of phloretic acid methyl ester (1) (>100 µM) and protocatechuic acid (4) (>100 µM) (Table 1 and Supplementary Materials Figure S1). The difference in cytotoxic profiles for each tested compound correlated with a dual Hoechst 33342/propidium iodide nuclear staining assay (Figure 2b,d,f,h,j), in which dead NCI-H460 cells were only observed when tested with cytotoxic concentrations. With these findings, the concentrations up to 10 µg mL$^{-1}$ or 10 µM were defined as the non-cytotoxic doses for all tested compounds.

### Table 1. Some bioactivities of phytochemicals derived from _V. bensonii_.

| Phytochemicals from _V. bensonii_ | Absolute IC$_{50}$ 1 | Fold Change in Cell Proliferation 2 | Wound-Healing Rate (h$^{-1}$) 3 | Anchorage Independence 4 | Fold Change in Survival | Fold Change in Growth |
|----------------------------------|----------------------|-----------------------------------|-------------------------------|------------------------|------------------------|------------------------|
| Crude methanolic extract         | 40.39 µg mL$^{-1}$    | 0.90                              | 0.16 ± 0.02                   | 0.56                   | 0.27                   |
| Phloretic acid methyl ester (1)  | >100 µM              | 0.80                              | 0.14 ± 0.01                   | 0.43                   | 0.20                   |
| Cymbinodin-A (2)                 | 50.82 µM             | 0.86                              | 0.17 ± 0.02                   | 0.69                   | 0.82                   |
| Ephemeranthoquinone B (3)        | 64.22 µM             | 0.85                              | 0.17 ± 0.02                   | 0.94                   | 0.96                   |
| Protocatechuic acid (4)          | >100 µM              | 1.04                              | 0.17 ± 0.02                   | 0.60                   | 0.76                   |

1 Cytotoxic effect of each _V. bensonii_ phytochemical on NCI-H460 cells was reported as the absolute half maximal inhibitory concentration (absolute IC$_{50}$) value derived from the sigmoidal dose-response plot (Supplementary Materials Figure S1). 2 NCI-H460 cell proliferation after treating with 10 µg mL$^{-1}$ or 10 µM of each _V. bensonii_ phytochemical for 48 and 72 h was assessed using crystal violet staining assay, while the fold change of proliferated cells from those of the vehicle control made of 0.5% (v/v) dimethyl sulfoxide (DMSO) was calculated. 3 The wound-healing rate of NCI-H460 cells after treating with each _V. bensonii_ phytochemical was computed based on linear regressions of reduced wound areas across times of detection, which represents the cell migration rate derived from three independent experiments—the results refer to means ± standard deviations. 4 The capability of NCI-H460 cells to survive and grow in the presence of 10 µg mL$^{-1}$ or 10 µM of each _V. bensonii_ phytochemical under anchorage-independent conditions was evaluated using the soft agar colony formation assay. After treating for 7 days, the fold changes in survival and growth of NCI-H460 colonies from those of the vehicle control made of 0.5% (v/v) DMSO were accounted based on the colony counts and sizes, respectively.

Protocatechuic acid (4): White powder; HR-ESI-MS: [M – H]$^-$ at m/z 153.0192 (calcd. for 153.0187, C$_7$H$_3$O$_2$); $^1$H NMR (400 MHz, methanol-$_d_4$): δ: 6.74 (1H, d, J = 8.4 Hz, H-5), 7.38 (1H, dd, J = 8.4, 2.0 Hz, H-6), 7.42 (1H, d, J = 2.0 Hz, H-2); $^{13}$C NMR (100 MHz, methanol-$_d_4$): δ: 173.9 (COOH), 150.1 (C-4), 145.7 (C-3), 127.9 (C-1), 123.5 (C-6), 117.9 (C-2), 115.5 (C-5) (Figure 1).
Figure 2. Cytotoxic effects of *Vanda bensonii* metabolites on the viability of NCI-H460 cells. Percentages of cell viability after treating cells with varying concentrations of *V. bensonii* metabolites for 24 h, assessed by a colorimetric method (a,c,e,g,i) and confirmed by a dual Hoechst 33342/propidium iodide.
V. bensonii metabolites affected NCI-H460 cell proliferation differently (Figure 3 and Table 1). Every tested compound did not show an inhibitory effect on NCI-H460 cell proliferation when testing for 24 h (Figure 3). Except for protocatechuic acid (4), other tested V. bensonii metabolites could decrease NCI-H460 cell proliferation after exposure for 48 h, although a significant reduction 0.80-fold lower than the vehicle control was only observed with the phloretic acid methyl ester (1) treatment (Figure 3 and Table 1). The anti-proliferation degree of NCI-H460 cells increased when extending the incubation time with V. bensonii metabolites to 72 h (Figure 3 and Table 1).

Migration and anchorage-independent growth of NCI-H460 cells in the presence of V. bensonii metabolites were assessed to unveil the impacts of these orchid metabolites on NSCLC cell metastasis. A wound-healing assay was conducted to investigate how V. bensonii compounds hampered NCI-H460 cell migration (Figure 4). The wound area decreased when the incubation time increased (Figure 4a). Changes in relative wound areas at 12 and 24 h to those measured at 0 h were not significantly different when compared among different V. bensonii metabolites (Figure 4b). When considering the wound-healing rate of NCI-H460 cells treated with each V. bensonii compound, the treatment with phloretic acid methyl ester (1) offered the maximum reduction (0.14 ± 0.01 h⁻¹) followed by the crude methanolic extract and cymbinodin-A (2) (Figure 4c and Table 1).
Figure 4. Impacts of *Vanda bensonii* metabolites on NCI-H460 cell migration. The capability of H460 cells to migrate in the presence of each tested compound (i.e., a crude extract, phloretic acid methyl ester (1), cymbinodin-A (2), ephemeranthoquinone B (3), and protocatechuic acid (4)) at 10 μg mL⁻¹ (for the crude extract) or 10 μM (for the isolated compounds) for different incubation durations was assessed by a wound-healing assay. (a) Representative images show the change in wound areas measured at different incubation times. (b) The change in wound areas was calculated and reported as the relative values to those detected at 0 h. (c) The wound-healing rate for each tested compound was also computed. All experiments were performed at least in triplicate, and 0.5% (v/v) dimethyl sulfoxide served as the vehicle control. The graphical results represent means ± standard errors, and statistical comparisons of means between each treatment and the control were conducted at α = 0.05, where ns = no significance, * = p < 0.05, and **** = p < 0.0001.

The capability of NCI-H460 cells to grow without anchorage in the presence of *V. bensonii* metabolites was assessed using a soft agar colony formation assay (Figure 5 and Table 1). The number and size of NCI-H460 colonies formed in the soft agar matrix represented the capability of NCI-H460 cells to survive and grow under anchorage-independent conditions, respectively. Varying sizes of NCI-H460 colonies formed in the soft agar after exposure to different tested compounds for 7 days were visualized and examined (Figure 5a). Except for ephemeranthoquinone B (3), other *V. bensonii* metabolites significantly decreased the number of NCI-H460 colonies, while the maximum reduction in NCI-H460 cell survival (0.43-fold lower than that of the vehicle control) was found in the treatment with phloretic acid methyl ester (1) (Figure 5b and
Table 1). A similar trend of results was observed with the sizes of NCI-H460 colonies exposed to V. bensonii metabolites, where the maximum size reduction 0.20-fold lower than that of the vehicle control was found with the phloretic acid methyl ester (1) treatment (Figure 5c and Table 1). However, cymbinodin-A (2) only significantly affected the number of NCI-H460 colonies but did not affect the colony sizes (Figure 5b,c). Protocatechual acid (4) showed greater effect on the survival of NCI-H460 cells than their growth under the anchorage-independent conditions (Figure 5b,c).

![Figure 5](image-url)

**Figure 5.** Impacts of *Vanda bensonii* metabolites on the anchorage-independent growth of NCI-H460 cells. The capability of H460 cells to grow without anchorage in the presence of each *V. bensonii* metabolite (i.e., a crude extract, phloretic acid methyl ester (1), cymbinodin-A (2), ephemeranthoquinone B (3), and protocatechual acid (4)) at 10 μg mL\(^{-1}\) (for the crude extract) or 10 μM (for the isolated compounds) for 7 days was assessed by a soft agar colony formation assay. (a) Representative images show varying sizes of H460 colonies formed. The differences in numbers (b) and sizes (c) of H460 colonies were computed. All experiments were performed at least in triplicate, and 0.5% (v/v) dimethyl sulfoxide served as the vehicle control. The graphical results represent means ± standard errors, and statistical comparisons of means between each treatment and the control were conducted at \(a = 0.05\), where ns = no significance, * = \(p < 0.05\), ** = \(p < 0.0005\), and *** = \(p < 0.0001\).

3. Discussion

All four isolated compounds (1–4) from *V. bensonii* have been reported to be isolated from a variety of sources [15–28], but the information regarding their roles in anticancer activities, especially for antimetastatic roles, is still limited. To develop secondary malignant sites, cancer cells migrate and invade into vascular and lymphatic systems [11,12,14]. These migrating cancer cells evolve anoikis resistance, which enables them to survive and grow without anchorage and to form new tumor sites after extravasation [29]. This migration capability and anchorage-independent survival and growth in cancer metastasis are recognized aggressive characteristics of cancerous cells, which becomes a critical burden in cancer therapy. Compounds that can inhibit migration, growth, and survival of cancer cells under both anchorage-dependent and anchorage-independent conditions...
would be promising pharmaceutical products to cure cancers. Our findings proved that crude methanolic extract and phloretic acid methyl ester (1) derived from *V. bensonii* exhibited the most distinguished inhibitory activities against growth and metastasis of human NSCLC cells.

Phloretic acid methyl ester (1) was found to be a product of phloretic acid transformation by human intestinal bacteria, while the precursor of such biotransformation is phlorizin, a common phenolic compound of apple trees [15]. Phloretic acid is also a predominant phenolic compound found in *Cucurbita pepo* (field pumpkin) flowers, and its methyl ester is a recognized insect attractant [16]. To our knowledge, pharmaceutical roles of phloretic acid methyl ester (1), especially for its anticancer activities, have yet been unknown. Our results firstly proved that this *V. bensonii* metabolite can lower viability, proliferation, migration, and anchorage-independent survival and growth of NCI-H460 cells. In comparison with the crude methanolic extract derived from *V. bensonii*, it is highly possible that phloretic acid methyl ester (1) is the key anticancer agent found in this plant. Strong anticancer activities of *V. bensonii*-derived crude methanolic extract would offer the feasibility of using this pool of bioactive compounds in cancer treatment. However, additional studies are yet required to assess its toxicity and healing capacity.

Cymbinodin-A (2) is a phenanthraquinone firstly found in an aloe-leafed orchid *Cymbidium aloifolium* [17] and recently found in another *Cymbidium* species—*Cymbidium finlaysonianum*—with a proposed revised chemical structure [18]. Li et al. [19] also found this compound in *Gastrodia elata*, an herbal composition of a Chinese “Tianshu” formula for migraine therapy. The compound possesses diverse bioactivities, including anticancer [18] and anti-collagenase properties [20]. The anticancer activity of this phytochemical was assessed with human small cell lung cancer (NCI-H187) cells, and its IC$_{50}$ value was 3.73 µM, which was greater and weaker than that of the positive controls, ellipticine (17.09 µM) and doxorubicin (0.24 µM), respectively [18]. *V. bensonii* also contains cymbinodin-A (2) and its closely related molecule, ephemeranthoquinone B (3) (Figure 1). Our study has proved that *V. bensonii* cymbinodin-A (2) can diminish the viability of human NSCLC (NCI-H460) cells with an IC$_{50}$ of 50.82 µM. This IC$_{50}$ value is higher than cisplatin (21.57 µM) as a positive control tested previously [30]. We first found that this phytochemical could also suppress the proliferation, migration, and anchorage-independent survival of NCI-H460 cells.

Another sister compound of cymbinodin-A (2), ephemeranthoquinone B (3), is firstly isolated from *Cymbidium Great Flower Marie ‘Laurencin’* roots [21] and subsequently isolated from *Odontioda Marie Noel ‘Velano’* [22] and *Cymbidium finlaysonianum* [18]. This phytochemical showed inhibitory activity against Gram-positive bacteria, human promyelocytic leukemia (HL-60) cells, human oral squamous cell carcinomas, and leukemic cells [21,22]. Masuda et al. [22] reported that anticancer activities of this compound were slightly higher than its cytotoxic effects on normal cell lines tested, and such cytotoxicity was not a result from apoptosis. *V. bensonii*-derived ephemeranthoquinone B (3) also showed mild cytotoxicity against NCI-H460 cells; however, dead cells confirmed by a nuclear staining method could be found when exposed to its cytotoxic doses. Additional investigations using high-resolution methods such as flow cytometry could be employed to discriminate modes of cell death (apoptosis and necrosis) caused by a tested molecule. Moreover, ephemeranthoquinone B (3) only affected NCI-H460 cell proliferation when exposed for 72 h (Figure 3) and did not inhibit migration and anchorage-independent growth of NCI-H460 cells (Figures 4 and 5). The difference in anticancer activities between this compound and its sister molecule, cymbinodin-A (2), is highly likely to be due to the difference in their chemical structures. Ephemeranthoquinone B (3) consists of a double bond at C-9 and C-10 (Figure 1), whereas there is no double bond at this position for cymbinodin-A (2).

Protocatechuic acid (4) [23] seems to be a common phenolic compound found in diverse orchid species [24–27], and it is a notable intermediate in de novo biosynthesis of vanillin—the principal component of the vanilla orchid [24]. Our studies proved that
protocatechuic acid (4) derived from V. bensonii showed no effect on the viability, proliferation, and migration of NCI-H460 cells (Figures 2–4), but it exerted some roles to limit anchorage-independent growth of these cancer cells (Figure 5). Surprisingly, Tsao et al. [31] unveiled that this compound posed inhibitory activities against diverse NSCLC cells (i.e., A549, H3255, and Calu-6), while the underlying molecular mechanisms involved the modulation of FAK, MAPK, and NF-κB pathways. The difference in these results relies significantly on the types of cancer cells tested. Another study demonstrated that this molecule from an edible mushroom, Clitocybe alexandri, could inhibit growth of NCI-H460 cells after treating for 48 h with an IC50 of 1616.0 ± 75.3 µM [28]. Our findings agreed with this report as we could not see the inhibitory effect of V. bensonii-derived protocatechuic acid (4) on NCI-H460 cell viability, even when treating with the maximum tested dose of 100 µM for 24 h.

4. Materials and Methods

4.1. Plant Materials

V. bensonii plants were purchased in August 2011 from Chatuchak market in Bangkok, Thailand. Plant specimens were identified by Prof. Thatree Phadungcharoen (Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University) and deposited with a specimen voucher (BS-VB-082554) at the same institute.

4.2. Chemicals and Reagents

All organic solvents for the phytochemical extraction and elucidation (i.e., methanol (MeOH), ethyl acetate (EtOAc), dichloromethane (DCM), acetone, hexane, and dimethyl sulfoxide (DMSO)) and other chemical reagents (i.e., 3-(4,5-Dimethylthiazol 2-yl)-2,5-diphenyltetrazolium bromide (MTT), Hoechst 33342, propidium iodide (PI), crystal violet, formaldehyde, and agarose powder) were purchased from Sigma-Aldrich (St. Louis, MO, USA).

4.3. Extraction, Fractionation, and Structural Elucidation of Key Phytochemicals

The whole air-dried V. bensonii plants (1.9 kg) were cut, pulverized, and extracted with MeOH (3 × 5 L) at ambient temperature. The resultant organic solvent was evaporated under reduced pressure to give a dried mass of 221 g. The methanolic extract was partitioned with EtOAc and water to give an EtOAc extract (65.4 g) and an aqueous extract, respectively. The EtOAc extract was thereafter fractionated by vacuum liquid chromatography (VLC) on a silica gel (hexane–ethyl acetate, gradient) to give 5 fractions (I–V). Fraction III (15 g) was separated by column chromatography (CC, silica gel, EtOAc–DCM gradient) to yield 6 fractions (IIIa–IIIf). VLC and CC were performed on a silica gel 60 (Merck, Kieselgel 60, 70–320 µm) and a silica gel 60 (Merck, Kieselgel 60, 230–400 µm) (Darmstadt, Germany), respectively. Fraction IIIId (26.2 mg) was further separated by CC (silica gel, hexane–acetone gradient) and then purified on a silica gel (hexane–MeOH gradient) to afford compound 1 (3.4 mg). Fraction V (24.5 mg) was separated on an EtOAc–DCM gradient to yield 9 fractions (Va–Vi). Thereafter, fraction Vh was further purified on a sephadex LH-20 column with acetone to obtain compound 2 (2.9 mg) and compound 3 (3.4 mg), respectively. Fraction Vi (8.0 mg) was fractionated by CC (silica gel, DCM–MeOH gradient) to obtain compound 4 (4.8 mg). Mass spectra were obtained on a Bruker micro TOF mass spectrometer (ESI-MS) (Billerica, MA, USA). NMR spectra were recorded on a Bruker Avance Neo 400 MHz NMR spectrometer (Billerica, MA, USA).

4.4. Cell Culture and Growth Conditions

Human non-small cell lung cancer NCI-H460 cells were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). NCI-H460 cells were cultured in the Roswell Park Memorial Institute (RPMI) (Gibco, Gaithersburg, MA, USA). The culture medium was supplemented with 2 mM L-glutamine, 10% (v/v) fetal bovine serum, and
100 units mL\(^{-1}\) penicillin/streptomycin. The cells were cultivated at 37 °C under a 5% CO\(_2\) stream up to 70–80% confluence before use in the experiments.

4.5. Cell Viability Assay

The effects of \(V.\) bensonii metabolites on the viability of NCI-H460 cells were assessed using an MTT assay [32]. Cells seeded into a 96-well plate at a density of \(8 \times 10^3\) cells/well were exposed to varying concentrations of \(V.\) bensonii metabolites for 24 h. Cells treated with 0.5% (\(v/v\)) DMSO served as a vehicle control. The assay medium was removed and replaced with 0.5 mg mL\(^{-1}\) of MTT solution made by dissolving the compound with phosphate-buffered saline (PBS) and the incubation was continued in the dark at 37 °C under a 5% CO\(_2\) stream for 3 h. The assay solution was then removed and replaced with DMSO to solubilize the formazan crystal formed prior to the measurement of absorbance at the 570 nm wavelength by using a microplate reader (Anthros, Durham, NC, USA). The absorbance values derived were used to calculate the percentage of cell viability relative to the vehicle control. The experiments were performed at least in triplicate.

A dual Hoechst 33342/propidium iodide nuclear staining assay [33] was also conducted to confirm cell death after treating with varying concentrations of \(V.\) bensonii metabolites. Cells were seeded and treated as described above. The assay medium was removed and replaced with PBS containing 2 \(\mu\)g mL\(^{-1}\) Hoechst 33342 and 1 \(\mu\)g mL\(^{-1}\) propidium iodide. The assay plate was incubated in the dark at 37 °C under a 5% CO\(_2\) stream for 30 min. The stained cells were visualized and photographed under a fluorescence microscope (Olympus IX51 with DP70, Tokyo, Japan). Cells stained with bright blue (of Hoechst 33342) and red (of propidium iodide) were defined as dead cells. The experiments were performed at least in triplicate.

4.6. Cell Proliferation Assay

The impacts of \(V.\) bensonii metabolites on the proliferation of NCI-H460 cells were investigated using a crystal violet staining method [33]. NCI-H460 cells were seeded into a 96-well plate at a density of \(2 \times 10^3\) cells/well and treated with a non-cytotoxic concentration of \(V.\) bensonii metabolites. The assay plate was incubated at 37 °C under a 5% CO\(_2\) stream for 24, 48, and 72 h. When reaching each incubation time, the assay medium was removed and replaced with 0.05% (\(v/v\)) crystal violet solution containing 1% (\(v/v\)) formaldehyde and the incubation continued at ambient temperature for 30 min. The staining solution was removed, and stained cells were washed thrice with deionized water. Remaining stained cells were air-dried overnight and dissolved with MeOH before measuring the absorbance at the 570 nm wavelength using a microplate reader. The absorbance value corresponded to the number of proliferated cells in each treatment. The experiments were performed at least in triplicate, and cells treated with 0.5% (\(v/v\)) DMSO served as vehicle controls.

4.7. Wound-Healing Assay

A wound-healing assay [34] was established to assess how \(V.\) bensonii metabolites affected NCI-H460 cell migration. Cells seeded into a 96-well plate at a density of \(6 \times 10^4\) cells/well were incubated at 37 °C under a 5% CO\(_2\) stream overnight. A wound made of a straight vertical line was formed by using a 20 \(\mu\)L pipette tip to scratch a cell monolayer at the center of each seeded well. The medium containing cell debris was removed and washed with PBS once. A non-cytotoxic concentration of each \(V.\) bensonii metabolite prepared by a dilution with RPMI medium was added to the assay well, while the one added to the medium containing 0.5% (\(v/v\)) DMSO served as a vehicle control. The settings were observed under a light microscope equipped with a camera (Nikon Ts2, Tokyo, Japan) and photographed to measure the wound area at 0, 12, and 24 h by using ImageJ software (https://imagej.nih.gov/ij/ accessed on 1 September 2022). The relative wound area to that measured at 0 h was computed, while the wound-healing rate referring
to the cell migration rate was estimated from the slope of the linear regression plotted by the wound areas at 0 to 24 h. The experiments were performed at least in triplicate.

4.8. Soft Agar Colony Formation Assay

The capability of V. bensonii metabolites to inhibit survival and growth of NCI-H460 cells under anchorage-independent conditions was investigated using a soft agar colony formation assay [35]. The soft agar with two layers was constructed in a 24-well plate, where bottom and top layers contained 0.5% and 0.3% (w/v) agarose (250 µL each), respectively. Both agar layers were prepared by diluting 1.5% (w/v) agarose with RPMI medium. The bottom layer was established up to 4 h prior to the top layer, which contained NCI-H460 cells at a density of 1.5 × 10^3 cells/well and each V. bensonii metabolite at a non-cytotoxic concentration or 0.5% (v/v) DMSO as a vehicle control. When the top agar layer was set, 250 µL of RPMI medium was added. The settings were incubated at 37 °C under a 5% CO₂ stream for one week with the addition of the medium every 3 days. When reaching the incubation time, NCI-H460 colonies formed in the agar were observed, counted, and photographed under the light microscope equipped with a camera. Derived photographs were used to measure the colony size with the ImageJ software. Colony number and size referred to the survival and growth capabilities of NCI-H460 cells under anchorage-independent conditions.

4.9. Statistical Analysis

Numerical results were presented as means ± standard deviations or standard errors and relative values to the control. The statistical comparison of means was conducted with one-way analysis of variance at α = 0.05, while a pairwise comparison of each mean to that of the control was processed with Tukey’s post hoc test. The statistical significance (p) of the difference in a pairwise comparison of means was determined as ns = no significance (p > 0.05), * = p < 0.05, ** = p < 0.01, *** = p < 0.0005, and **** = p < 0.0001. All statistical analyses were conducted with GraphPad Prism 8.0.2 software (San Diego, CA, USA).

5. Conclusions

Four phytochemicals, including phloretic acid methyl ester (1), cymbinodin-A (2), ephemeraanthoquinone B (3), and protocatechuic acid (4), were isolated from the whole plant methanolic extract of V. bensonii. These compounds and the crude methanolic extract demonstrated varying bioactivities to inhibit growth and metastasis of NCI-H460 cells. Overall, the crude extract and phloretic acid methyl ester (1) offered the greatest bioactivities to limit the viability, proliferation, migration, and anchorage-independent survival and growth of these lung cancer cells. To this end, it is proved that V. bensonii is a promising source of bioactive molecules possessing anticancer potential, which can be developed further as pharmaceutical products to optimize the future pharmacotherapy of lung cancer. Additional studies to unveil the molecular mechanisms underlying such anticancer activities of these V. bensonii metabolites and in vivo assessments are essential to fill the knowledge gaps in their pharmaceutical applications.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules27227902/s1, Figure S1: Sigmoidal dose-response plots of NCI-H460 cells treated with varying concentrations of Vanda bensonii metabolites.

Author Contributions: Conceptualization, C.C. (Chatchai Chaotham) and B.S.; methodology, N.N., R.S., C.C. (Chatchai Chaotham) and B.S.; software, R.S. and C.C. (Chatchai Chaotham); validation, R.S., C.C. (Chatchai Chaotham) and B.S.; formal analysis, T.O.J., N.N., R.S., C.C. (Chaisak Chansriniyom), K.L., P.C. and B.S.; investigation, T.O.J., N.N., R.S. and B.S.; resources, C.C. (Chatchai Chaotham) and B.S.; data curation, R.S., C.C. (Chatchai Chaotham) and B.S.; writing—original draft preparation, T.O.J. and R.S.; writing—review and editing, R.S., C.C. (Chatchai Chaotham) and B.S.; visualization, R.S., C.C. (Chatchai Chaotham) and B.S.; supervision, C.C. (Chatchai Chaotham) and B.S.; funding acquisition, C.C. (Chatchai Chaotham) and B.S. All authors have read and agreed to the published version of the manuscript.
Funding: This research is funded by the Thailand Science Research and Innovation Fund Chulalongkorn University (CU_FRB65_hea (57)066_33_10 and CU_FRB65_hea (60)069_33_13).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: T.O.J. is grateful to the Graduate School, Chulalongkorn University for the CU ASEAN and NON-ASEAN graduate scholarship. We thank the Research Instrument Center of the Faculty of Pharmaceutical Sciences, Chulalongkorn University for providing all research facilities. N.N. and R.S. have funding support from the Second Century Fund (C2F) of Chulalongkorn University. We thank Thatree Phadungcharoen for plant identification.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are not available from authors.

References
1. Gardiner, L.M.; Kocyan, A.; Motes, M. Molecular phylogenetics of Vanda and related genera (Orchidaceae). *Bot. J. Linn. Soc.* 2013, 173, 549–572. [CrossRef]
2. Hossain, M.M. Therapeutic orchids: Traditional uses and recent advances—An overview. *Fitoterapia* 2011, 82, 102–140. [CrossRef] [PubMed]
3. Khan, H.; Belwal, T.; Tariq, M.; Atanasov, A.G.; Devkota, H.P. Genus Vanda: A review on traditional uses, bioactive chemical constituents and pharmacological activities. *J. Ethnopharmacol.* 2019, 229, 46–53. [CrossRef] [PubMed]
4. Joshi, P.R.; Paudel, M.R.; Chand, M.B.; Pradhan, S.; Pant, K.K.; Joshi, G.P.; Bohara, M.; Wagner, S.H.; Pant, B.; Pant, B. Cytotoxic effect of selected wild orchids on two different human cancer cell lines. *Heliyon* 2020, 6, e03991. [CrossRef]
5. Lertnitikul, N.; Pattamadilok, C.; Chansriniyom, C.; Suttisri, R. A new dihydrophenanthrene from *Cymbidium finlaysonianum* and related genera (Orchidaceae). *Mol. Clin. Oncol.* 2015, 3, 217–221. [CrossRef]
6. Zimmermann, S.; Dziadziuszko, R.; Peters, S. Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. *Cancer Treat. Rev.* 2014, 40, 716–722. [CrossRef]
7. Zhang, L.Q.; Yang, X.W.; Zhang, Y.B.; Zhai, Y.Y.; Xu, W.; Zhao, B.; Liu, D.L.; Yu, H.J. Biotransformation of phlorizin by human intestinal flora and inhibition of biotransformation products on tyrosinase activity. *Food Chem.* 2021, 347, 1–8. [CrossRef]
8. Zhang, L.; Yang, X.; Zhang, Y.B.; Zhai, Y.Y.; Xu, W.; Zhao, B.; Liu, D.L.; Yu, H.J. Biotransformation of phlorizin by human intestinal flora and inhibition of biotransformation products on tyrosinase activity. *Mol. Clin. Oncol.* 2015, 3, 217–221. [CrossRef]
9. Barua, A.K.; Ghosh, B.B.; Ray, S.; Patra, A. Cymbinodin-A, a phenanthraquinone from *Cymbidium aloifolium* and *Pleione sw. cultivation by-products. Circular economy in North Aegean Island of Samos. *Afr. J. Biotechnol.* 2012, 11, 11772–11781.
10. Ecoy, G.A.U.; Chammn, S.; Suwanborirux, K.; Chanvorachote, P.; Chaoham, C. Jorunnamycin A from *Cymbidium finlaysonianum* and *Vanda roxburghii* (Roxb). *J. Nat. Prod.* 2018, 81, 251–301. [CrossRef]
11. Tamura, T.; Kurishima, K.; Nakazawa, K.; Kogohashi, K.; Ishikawa, H.; Satoh, H.; Hizawa, N. Specific organ metastases and related genes in human lung cancer cells. *J. Ethnopharmacol.* 2015, 167, 209–211.
12. Metcalf, R.L.; Kogan, M. Plant volatiles as insect attractants. *Crit. Rev. Plant Sci.* 1987, 5, 251–301. [CrossRef]
13. Barua, A.K.; Ghosh, B.B.; Ray, S.; Patra, A. Cymbinodin-A, a phenanthraquinone from *Cymbidium aloifolium*. *Phytochemistry* 1990, 30, 3046–3047. [CrossRef]
14. Lertnitikul, N.; Pattamadilok, C.; Chansriniyom, C.; Suttisri, R. A new dihydrophenanthrene from *Cymbidium finlaysonianum* and related genera, and structure revision of cymbinodin-A. *J. Asian Nat. Prod. Res.* 2020, 22, 83–90. [CrossRef]
15. Li, Y.; Zhang, J.; Zhang, L.; Chen, X.; Fan, Y.; Chen, S.S.; Zhang, S.; Wang, Z.; Xiao, W.; Yang, L.; et al. Systems pharmacology to decipher the combinational anti-migraine effects of Tianshu formula. *J. Ethnopharmacol.* 2015, 174, 45–56. [CrossRef]
16. Axiotis, E.; Angelis, A.; Antoniadi, L.; Petraris, E.; Skaltsounis, L.A. Phytochemical analysis and dermo-cosmetic evaluation of *Cymbidium Sw.* cultivation by-products. Circular economy in North Aegean Island of Samos. *Planta Med.* 2021, 87, 1288.
17. Yoshikawa, K.; Ito, T.; Iseki, K.; Baba, C.; Imagawa, H.; Yagi, Y.; Morita, H.; Asakawa, Y.; Kawano, S.; Hashimoto, T. Phenanthrene derivatives from *Cymbidium Great Flower Marie Laurencin* and their biological activities. *J. Nat. Prod.* 2012, 75, 605–609. [CrossRef]
22. Masuda, Y.; Suzuki, R.; Sakagami, H.; Umemura, N.; Shirataki, Y. Novel cytotoxic phenanthrenequinone from *Odontioda* Marie Noël ‘Velano’. *Chem. Pharm. Bull.* 2012, 60, 1216–1219. [CrossRef]

23. Benahmed, M.; Akkal, S.; Elomri, A.; Laouer, H.; Vérité, P.; Seguin, E. Constituents from *Bupleurum montanum* (Coss. & Dur.) (Apiaceae). *Arab. J. Chem.* 2014, 7, 1065–1069.

24. Gallage, N.J.; Möller, B.L. Vanillin–bioconversion and bioengineering of the most popular plant flavor and its de novo biosynthesis in the vanilla orchid. *Mol. Plant* 2015, 8, 40–57. [CrossRef] [PubMed]

25. Minh, T.N.; Khang, D.T.; Tuyen, P.T.; Minh, L.T.; Anh, L.H.; Quan, N.V.; Ha, P.T.T.; Quan, N.T.; Toan, N.P.; Elzaawely, A.A.; et al. Phenolic compounds and antioxidant activity of *Phlaenopsis* orchid hybrids. *Antioxidants* 2016, 5, 31. [CrossRef] [PubMed]

26. Bhattacharyya, P.; Kumar, V.; Grüz, J.; Doležal, K.; Van Staden, J. Deciphering the phenolic acid reserves and antioxidant activity within the protocorm like bodies of *Ansellia africana*: A vulnerable medicinal orchid. *Ind. Crops Prod.* 2019, 135, 21–29. [CrossRef]

27. Kotiloğlu, D.; Acet, T.; Özcan, K. Phytochemical profile and biological activity of a therapeutic orchid from Anatolia: *Dactylorhiza romana* subsp. *georgica*. *J. Food Meas. Charact.* 2020, 14, 3310–3318. [CrossRef]

28. Vaz, J.A.; Almeida, G.M.; Ferreira, I.C.; Martins, A.; Vasconcelos, M.H. *Clitocybe alexandri* extract induces cell cycle arrest and apoptosis in a lung cancer cell line: Identification of phenolic acids with cytotoxic potential. *Food Chem.* 2012, 132, 482–486. [CrossRef]

29. Guadamillas, M.C.; Cerezo, A.; Del Pozo, M.A. Overcoming anoikis–pathways to anchorage-independent growth in cancer. *J. Cell Sci.* 2011, 124, 3189–3197. [CrossRef]

30. Jimoh, T.O.; Costa, B.C.; Chansriniyom, C.; Chaotham, C.; Chanvorachote, P.; Rojsitthisak, P.; Likhitwitayawuid, K.; Sritularak, B. Three new dihydrophenanthrene derivatives from *Cymbidium ensifolium* and their cytotoxicity against cancer cells. *Molecules* 2022, 27, 2222. [CrossRef]

31. Tsao, S.M.; Hsia, T.C.; Yin, M.C. Protocatechuic acid inhibits lung cancer cells by modulating FAK, MAPK, and NF-κB pathways. *Nutr. Cancer* 2014, 66, 1331–1341. [CrossRef]

32. Marks, D.C.; Below, L.; Davey, M.W.; Davey, R.A.; Kidman, A.D. The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells. *Leuk. Res.* 1992, 16, 1165–1173. [CrossRef]

33. Khine, H.E.E.; Sunghthong, R.; Sritularak, B.; Promphetchara, E.; Chaotham, C. Untapped pharmaceutical potential of 4, 5, 4′-trihydroxy-3, 3′-dimethoxybibenzyl for regulating obesity: A cell-based study with a focus on terminal differentiation in adipogenesis. *J. Nat. Prod.* 2022, 85, 1591–1602. [CrossRef] [PubMed]

34. Rodriguez, L.G.; Wu, X.; Guan, J.L. Wound-healing assay. In *Cell Migration*; Humana Press: Totowa, NJ, USA, 2005; pp. 23–29.

35. Borowicz, S.; Van Scoy, M.; Avasarala, S.; Rathinam, M.K.K.; Tauler, J.; Bikkavilli, R.K.; Winn, R.A. The soft agar colony formation assay. *J. Vis. Exp.* 2014, 92, e51998. [CrossRef] [PubMed]